Reuters logo
a year ago
BRIEF-AstraZeneca says U.S. FDA grants orphan drug status for potential eye drug
March 9, 2016 / 7:28 AM / a year ago

BRIEF-AstraZeneca says U.S. FDA grants orphan drug status for potential eye drug

March 9 (Reuters) - AstraZeneca Plc :

* AstraZeneca's potential medicine for neuromyelitis optica receives FDA orphan drug designation

* US FDA has granted orphan drug designation for investigational anti-cd19 monoclonal antibody, medi-551

* Developed by Medimmune, Medi-551 is currently in phase IIb clinical development for NMO Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below